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Introduction and Objectives: 
Lower limb muscle strength measured by Quadriceps Maximal Voluntary Contraction (QMVC) 
provides valuable functional and prognostic information in people with COPD. Reference equations 
providing normal values for QMVC have been reported, some requiring an assessment of muscle 
mass and others not, but it is unclear whether the inclusion of muscle mass significantly alters 
predicted values in COPD We addressed this question by deriving reference equations for QMVC 
with and without the inclusion of whole body assessment of muscle mass in a cohort of healthy 
volunteers and subsequently comparing QMVC assessment in two separate cohorts of patients with 
COPD using these reference equations.  
 
Methods 
Prediction equations were derived through multiple linear regression in a healthy control (HC) group. 
Age, gender, height and weight were inputted into the first model (FFM- model) and fat-free mass 
added for the other (FFM+ model). The prediction equations were then applied to a Primary Care 
COPD (PCC) group and Complex care COPD (CCC) group of patients where percentage predicted 
values were calculated and weakness determined using a threshold of the lower limit of normal. 
 
Results: 
175 HC subjects (median (IQR) age: 54 (14) years, 31% male) were recruited. The PCC group 
comprised 87 subjects (median (IQR) age: 68 (9) years, 71% male, FEV1 62 (20)% predicted) and 
the CCC group 189 subjects (median (IQR) 66 (12) years, 57% male, FEV1: 29 (16)% predicted).  
Prediction values for the HC and PCC were similar between the FFM- and FFM+ models as shown in 
the table. In the CCC percentage predicted values were lower and there were 11.9% more classed as 
weak by the FFM- model compared to the FFM+ model. 
 
 
Conclusion: 
The inclusion of fat-free mass did not significantly alter prediction values in the healthy cohort. In 
people with COPD, including FFM in the model altered the proportion of patients classified as having 
muscle weakness most notably in the CCC cohort. This is likely to be due to a higher prevalence of 
muscle wasting in this population which resulted in an underestimate of predicted strength when 
muscle mass is included in the model.  
 
 
 
Table: QMVC values expressed as percent predicted values and number classed as 
weak using the FFM- and FFM+ models for the COPD cohorts 
 
 Healthy Control Primary Care 
COPD 
Complex Care COPD 
  
n=175 
 
n=87 
 
n=189 
    
FFM- Model  
%pred QMVC: 
  
 
100.3 (24.1) 
 
86.0 (22.0) 
 
54.0 (16.4) 
Number classed as 
weak (%): 
6 (3.4%) 14 (16.3%) 101 (53.2%) 
 
FFM+ Model 
%pred QMVC: 
 
 
 
100.2 (24.1) 
 
 
86.7 (20.6) 
 
 
59.2 (17.8) 
Number classed as 
weak (%): 
8 (4.6%) 10 (11.6%) 78 (41.3%) 
Mean (SD) values presented as a percentage of the values predicted (%pred) using the FFM- and 
FFM+ models. Abbreviations: FFM+: Fat-free mass included, FFM- fat-free mass not included. 
 
 
 
 
 
 
